EMEA reviews policy on conflicts of interest
This article was originally published in SRA
Executive Summary
Ongoing discussions on the European Medicines Agency’s policy on handling conflicts of interest relating to experts appointed to the scientific advisory groups that provide advice on specific types of medicinal products or treatments to the agency’s Committee for Medicinal Products for Human Use are likely to lead to a revision of the policy1.